



# Nutrition, Gut Microbiota, and Alzheimer's Disease

Mariana Romanenko<sup>1\*</sup>, Victor Kholin<sup>2</sup>, Alexander Koliada<sup>3</sup> and Alexander Vaiserman<sup>4</sup>

<sup>1</sup> Laboratory of Dietetics, D.F. Chebotarev State Institute of Gerontology NAMS of Ukraine, Kyiv, Ukraine, <sup>2</sup> Department of Age Physiology and Pathology of the Nervous System, D.F. Chebotarev State Institute of Gerontology NAMS of Ukraine, Kyiv, Ukraine, <sup>3</sup> Molecular Genetic Laboratory Diagen, Kyiv, Ukraine, <sup>4</sup> Laboratory of Epigenetics, D.F. Chebotarev State Institute of Gerontology NAMS of Ukraine, Kyiv, Ukraine

Nutrition is known to play an important role in the pathogenesis of Alzheimer's disease. Evidence is obtained that the gut microbiota is a key player in these processes. Dietary changes (both adverse and beneficial) may influence the microbiome composition, thereby affecting the gut-brain axis and the subsequent risk for Alzheimer's disease progression. In this review, the research findings that support the role of intestinal microbiota in connection between nutritional factors and the risk for Alzheimer's disease onset and progression are summarized. The mechanisms potentially involved in these processes as well as the potential of probiotics and prebiotics in therapeutic modulation of contributed pathways are discussed.

## OPEN ACCESS

### Edited by:

Hanafi Ahmad Damanhuri,  
National University of  
Malaysia, Malaysia

### Reviewed by:

Cristiano Capurso,  
University of Foggia, Italy  
Bruno Pietro Imbimbo,  
Chiesi Farmaceutici, Italy

### \*Correspondence:

Mariana Romanenko  
maryanar@ukr.net

### Specialty section:

This article was submitted to  
Aging Psychiatry,  
a section of the journal  
Frontiers in Psychiatry

**Received:** 21 May 2021

**Accepted:** 12 July 2021

**Published:** 05 August 2021

### Citation:

Romanenko M, Kholin V, Koliada A and Vaiserman A (2021) Nutrition, Gut Microbiota, and Alzheimer's Disease. *Front. Psychiatry* 12:712673. doi: 10.3389/fpsy.2021.712673

**Keywords:** nutrition, gut microbiota, cognitive function, dementia, Alzheimer's disease

## INTRODUCTION

Over 50 million people worldwide were living with dementia in 2019 and their number is expected to rise to 152 million in 2050 (1). Dementia, particularly Alzheimer's disease (AD), as the major cause of disability and dependence in elderly persons lead to a significant negative socioeconomic impact (2). In 2015, the global costs of dementia increased to 818 billion of US dollars and estimated costs in 2030 can reach about 2 trillion US dollars (3). Among the multiple risk factors identified for AD the presence of potentially modified cardiometabolic risk factors opens the opportunities to impact them through dietary modification (4, 5). Moreover, recent evidence indicates that imbalances in the gut microbiota (GM) can be also associated with the neurodegeneration (6, 7). So, the GM appears to be an attractive aim for prevention or treatment of AD (8–10). In this context, modulation of the GM composition offers diet a strong potential (6, 11).

## NUTRITION AND ALZHEIMER'S DISEASE

In the last decades, the influence of dietary factors on cognitive function has become the subject of active research in pre-clinical and clinical studies. Various nutritional approaches have demonstrated a potential impact to prevent or slow down neurodegeneration or improve certain cognitive capacities. Accordingly, some benefits for cognitive performance may be found for vitamins E, D, B-group vitamins, various polyphenols, carotenoids, capsaicin, n-3 polyunsaturated fatty acids (PUFAs) and monosaturated fatty acids (MUFAs), some food and dietary patterns (12, 13).

## Food Group

The relationships between the consumption of various food groups and cognitive health has been investigated for many years. Currently, studies of the various foods impact on cognitive performance mostly report mixed data. Vegetable intake was correlated with better cognitive score in a prospective cohort study or with larger cortical thickness in a cross-sectional study (14, 15). Consumption of vegetables was also shown to improve orientation ability in cognitively healthy adults or adults with mild cognitive impairment (MCI) (16). Positive impact of vegetables on cognitive performance is thought to be attributed to high content of carotenoids, polyphenols, other antioxidants and fiber.

Animal protein food is of interest as it is a significant source for the formation of neurotransmitters or neurotoxic substances by the GM (17). However, fish consumption seems to affect cognitive function positively. In cognitively healthy elderly individuals higher fish intake was associated with larger cortical thickness or larger total gray matter volume (15, 18). Elderly adults with fish consumption  $\geq 1$  servings/week had a slower rate of cognitive decline (19). Nevertheless, in other study no evidence was found for fish to prevent age-related cognitive impairment (20). In meta-analysis by Bakre et al. a 20–30% decrease in the risk of dementia and AD in people who eat fish was reported (21). The potential benefits of fish intake are considered to be linked to the n-3 PUFAs content in marine fish (12). N-3 PUFAs were shown to diminish amyloid-beta (A $\beta$ ) peptide aggregation, increase A $\beta$  clearance, modulate synaptic plasticity and Tau phosphorylation, and decrease neuroinflammation (22–26). Existing findings indicate that n-3 PUFAs may also influence the GM composition and intestinal barrier integrity (27, 28). Interestingly, cognitive changes induced by dietary n-3 PUFAs deficiency correlated with microbiota composition and inflammatory status in an animal study (29). However, in the systematic review by Rangel-Huerta et al. evidence that n-3 PUFAs supplementation can prevent or slow down AD in older adults appeared to be inconclusive (30).

Consumption of dairy and meat is thought to impact negatively on cognition, as a high intake of this protein sources is part of the unhealthy Western-style diet. Nonetheless, Ngabirano et al. found that elderly people who consumed meat  $\leq 1$  time/week were at an increased AD risk. Moreover, low meat consumers also ate less fish, fruit and vegetables, therefore, they could have low dietary intake in general and some nutritional deficiencies (31). No strong association between meat consumption and cognitive decline was observed in the meta-analysis by Zhang et al. (32).

Currently, several reviews failed to find a dose-response effect of milk and dairy consumption on cognitive performance (33, 34). In part, the mixed findings can be explained by methodological heterogeneity of studies included and the existence of opposing consumption patterns in countries with different dairy cultures such as Japan and the US, for example (35, 36). Concerns about dairy consumption are related to their D-galactose content since excess D-galactose has been shown to impair neuronal function (37). Interestingly, interventions with probiotics (38) or antioxidants (39, 40) may attenuate D-galactose-induced brain senescence in animal studies.

## Dietary Pattern

Accumulating evidence indicates that combinations of foods and nutrients might have a synergistic effect and thus more benefits on cognitive function than individual components. This may be due to the improved micronutrient intake and overall health and, of course, better microbiota composition in people adherent to healthy diet. Some dietary patterns such as Mediterranean diet (MeD), Dietary Approaches to Stop Hypertension (DASH) and Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) were associated with improved cognitive scores in population aged  $\geq 40$  y (12, 41, 42). MeD, DASH and MIND are plant-based diets with moderate to high consumption of fish, whole grains, vegetables and fruit, nuts and limited amount of red meat and sweets. Some differences between these diets lie in the amounts of other foods and nutrients (41–44). Higher adherence to MeD was associated with lower brain atrophy in non-demented elderly adults (15, 18). In the meta-analysis by van den Brink et al. higher MeD adherence decreased AD risk in case-control and longitudinal studies (42). The longitudinal studies showed a lower AD risk for high adherence to the DASH and MIND diets and for moderate adherence to the MIND diet (45, 46). Of note, the mentioned dietary patterns are high in fiber promoting the growth of healthy GM. Moreover, these diets contain nutrients associated with antioxidant and anti-inflammatory properties and suppression of A $\beta$  deposition, including n-3 PUFAs, vitamin E, folate, carotenoids, and polyphenols (44, 47). Elevated MUFAs consumption as part of MeD and MIND diets is also considered to be beneficial for reducing the dementia risk (12, 48).

## GUT MICROBIOTA COMPOSITION AND ALZHEIMER'S DISEASE

The previous data showed that the detrimental changes in the GM composition result in increase of intestinal permeability and systemic inflammation, which negatively affects the blood-brain barrier integrity (49–51). Further, bacterial lipopolysaccharides (LPS) and proinflammatory cytokines may activate microglia and accelerate neuroinflammation which contributes to a neuronal loss (7, 52–54). Activation of intestinal NLRP3 by gut flora was also shown to be involved into AD pathogenesis. In animal model upregulation of NLRP3 inflammasome after fecal microbiota transplantation (FMT) from AD patients lead to activation of systemic inflammation and neuroinflammation in the hippocampus (55). The most discussed potential mechanisms of GM impact on AD risk are associated with active metabolites and signaling molecules such as: trimethylamine N-oxide (TMAO) (56, 57), bile acids (58, 59), dysregulated P-glycoprotein (60), kynurenine (61), and nuclear factor- $\kappa$ B-sensitive microRNA-146a (62).

In addition, bacterial amyloid proteins prime the immune system, thus triggering an immune response to the brain amyloids and promoting the alpha-synuclein aggregation (63, 64). Therefore, an increasing number of studies are devoted to the relationship between AD and GM. Significant changes in the GM were demonstrated in many studies on AD

mouse models. For example, 27 bacterial species from six phylogenetic groups differed in SAMP8 mice compared to the control (65). Significant differences in the GM composition were also revealed for AD patients, both at the phylum and species levels. Quantitative differences between AD patients and healthy participants were found in 13 bacterial genera. In particular, AD patients showed an increase in the number of bacteria belonging to *Proteobacteria* and *Bacteroidetes* phyla, together with a decrease in the representatives of *Firmicutes* and *Actinobacteria* phyla. Additionally, researchers demonstrated an association between the presence of some genera in the gut and AD markers, such as A $\beta$ 42/A $\beta$ 40 and A $\beta$ /p-tau ratio (66). Noted remarkable differences in the bacterial diversity in the AD patients' intestines compared to healthy people were revealed in terms of taxonomic groups such as *Bacteroides*, *Actinobacteria*, *Ruminococcus*, *Lachnospiraceae*, and *Selenomonadales* (67). An increase of genera *Escherichia-Shigella*, a member of *Enterobacteriaceae*, and reduction of SCFA-producing genera was found by Hou et al. (68). In another study, AD patients showed higher prevalence of proinflammatory taxa and lower abundance of butyrate-producing species, such as members of the *Butyrivibrio* and *Eubacterium* genera, as well as *Clostridium sp.* strain SY8519, *Roseburia hominis*, and *Faecalibacterium prausnitzii* (60). Notably, infection with certain pathogens including representatives of the oral or gut microbiome such as *Helicobacter pylori*, *Porphyromonas gingivalis*, *Candida albicans*, *Candida glabrata*, and others were found to be associated with AD risk (69).

Due to obvious differences in the microbiome composition, the first attempts to use microbial signatures as markers of AD are being made (70). For example, a model that uses 20 typical predominant genera can effectively distinguish patients with AD and MCI from healthy individuals. Moreover, five functional orthologs which differed in AD patients were identified by using metagenomic data. The samples obtained from AD patients showed a deficit of orthologs engaged into the biosynthesis of the amino acids involved in the metabolism of neurotransmitters (71). These results are in line with other studies which revealed the dysregulation of tryptophan metabolic pathways in AD patients (72, 73).

## MICROBIOTA-MEDIATED LINK BETWEEN NUTRITION AND ALZHEIMER'S DISEASE

Nutrition is one of the main factors that influence the GM composition throughout the life course (74, 75). In turn, microbiota mediate interplay between habitual diet and various processes of a host organism, including cognitive performance (6, 10). In this context the GM may interact with dietary factors by contributing to energy homeostasis and metabolic risk factors and modulating systemic inflammatory response through dietary metabolites and also affecting the availability of nutrients which are important for brain functioning (49, 50, 52, 76). **Figure 1** summarizes the potential effects of nutrition and the GM on the AD risk.

## Short-Chain Fatty Acids


A positive impact of GM on neuronal homeostasis is associated with short-chain fatty acids (SCFAs) derived from non-digested polysaccharides (77). SCFAs were shown to affect brain functions directly by improving blood-brain barrier integrity and affecting glial cells or indirectly by modulating the immune response, and activating vagal and humoral pathways of the gut-brain axis (78–81). SCFAs such as acetate, propionate, and butyrate regulate many cellular functions via binding to G-protein-coupled receptors (82). Moreover, acetate and butyrate are also well-known inhibitors of histone deacetylases, which activity is associated with cellular aging (83, 84). Anti-inflammatory and neuroprotective capacities of SCFAs were found mainly in animal studies or *in vitro* (85–87). In contrast, in one study increased A $\beta$  plaque deposition was demonstrated in germ free AD mice fed with SCFAs (88). In human studies acetate and valerate as well as bacterial LPS were connected with an enhanced amyloid deposition in the brain. Conversely, a high serum level of butyrate was found to be associated with fewer amyloid plaques (89).

## Polyphenols

Current findings indicate that GM closely interacts with dietary polyphenols using them as a food source for its own growth and providing new microbiota-derived metabolites. Thus, dietary polyphenols were shown to promote growth of *Lactobacillus spp.* and *Bifidobacterium spp.* and inhibited potentially pathogenic species (90, 91). On the other hand, GM potentially enhances the bioavailability of phenolic metabolites to the host (92, 93). Benefits of polyphenols and their metabolites in prevention of cognitive decline associated with its anti-inflammatory properties were reported previously (94–97). For example, gallic acid, which is a bacterial-derived metabolite of anthocyanins, was shown to decrease A $\beta$  deposition, reduce neuroinflammation and oxidative stress in brain of AD mice (98). Noteworthy that polyphenols and their metabolites may enhance the intestinal barrier integrity and thus decrease the local and systemic inflammation (99–101). Accordingly, the GM activity contributes to cognitive promotion effect of polyphenol-rich dietary patterns like MeD, DASH, and MIND. Particularly, a positive association between certain phenolic compounds and abundance of a butyrate-producing *Faecalibacterium prausnitzii* was found in healthy adults adherent to MeD (102).

## Trimethylamine-N-oxide

TMAO, which is a bacterial-derived metabolite of dietary choline, betaine and l-carnitine, was shown to be related to cognitive decline and AD (56, 57). An increased TMAO level in cerebrospinal fluid was found in individuals with MCI as well as with AD. Moreover, elevated TMAO in the cerebrospinal fluid was associated with markers of neurodegeneration (57). It is suggested that the TMAO blood level may depend on various factors, including the diet, GM composition, liver enzymes activity and urinary excretion (103, 104). However, the interaction between TMAO, its precursors, and neurodegeneration remains not fully understood. All of TMAO dietary substrates were previously found to be beneficial for



**FIGURE 1** | The role of nutrition and gut microbiota in the pathogenesis of Alzheimer's disease.

the cognitive function (105–110). Systematic reviews and meta-analyses elucidating the impact on cognition of food rich in TMAO precursors such as meat, eggs, dairy products, and marine fish demonstrated mixed results, although fish intake seemed to improve cognitive performance (12, 21, 32–34). Interestingly, marine fish already contains an increased amount of TMAO (103, 111). Studies with food or supplements rich in TMAO precursor failed to increase fasting plasma TMAO in young healthy adults (112, 113). Despite this, a concomitant increase in plasma choline, betaine and gamma-butyrobetaine was observed in study by Berge et al. (112). Switching to the MeD did not affect fasting TMAO, choline, betaine, and carnitine in healthy adults with an increased colon cancer risk (114). However, in another study daily red meat consumption (meat protein was 12% of daily energy) elevated TMAO concentration in plasma and urine. Moreover, red meat intake decreased TMAO renal excretion (115). Thus, it remains unclear whether consumption of TMAO precursors should be restricted for better cognitive performance.

Current findings showed that the impact of microbiota on TMAO metabolism may be related to an abundance of strains producing trimethylamine (TMA). Among the TMA-producing species belonging to *Firmicutes* and *Proteobacteria* phyla the representatives of *Clostridium*, *Escherichia*, and *Proteus* genera were identified (116). It is notable that cognitive impaired patients with A $\beta$  deposition had higher abundance of the genus

*Escherichia/Shigella* as compared to A $\beta$  negative patients and healthy controls (117). In other studies, healthy individuals with a higher *Firmicutes* to *Bacteroidetes* ratio demonstrated an increased production of TMAO from choline and carnitine rich food (118, 119). Negative correlation was found between the *Akkermansia mucinophilia* presence and fasting plasma TMAO in healthy adults at risk for colon cancer (114). Additionally, the GM was shown to regulate TMAO production via the impact on converting enzyme activity in the liver (117). However, in other neurodegenerative diseases lower plasma TMAO was reported to have worse prognostic implications (120, 121). Altogether, the existing data indicate that the interaction between TMAO, its precursors and cognitive impairment is more complex than a direct link and GM may play in it one of the key roles.

## Prebiotics and Probiotics

The modulation of systemic inflammatory response with prebiotics and probiotics can be part of a comprehensive approach to slow down the cognitive decline through an impact on gut-brain axis (122, 123). A positive effect on cognitive performance for diets rich in fiber and polyphenols can partially be attributed to the prebiotic properties of the mentioned nutrients. Studies on AD mouse models revealed neuroprotective effects for some non-digested fermentable carbohydrates, such as mannan oligosaccharide (124), *Morinda*

*officinalis* oligosaccharides (125), xylooligosaccharides (126), yeast  $\beta$ -glucans (127), lactulose and trehalose (128). Currently, human studies of prebiotics impact on cognitive function in AD patients are scarce.

Animal studies on probiotics showed that feeding with *Bifidobacterium breve* A1 restored the impaired cognitive behavior and suppressed neuroinflammation in the hippocampus of AD mice (129). Human interventions with *Bifidobacteria spp.* revealed an improvement in cognitive scores under up to 6 months supplementation in elderly adults with MCI (130, 131). The interventions with probiotics in AD individuals as of today are quite limited but still promising. Short-term supplementation with multispecies probiotic did not change cognitive scores in AD patients but affected the microbiome leading to an increase in *Faecalibacterium prausnitzii* and decreased intestinal permeability. A concomitant increase in serum neopterin and tryptophan breakdown marker could indicate the stimulation of the immune system (132). In small research of supplementation with probiotic-fermented milk AD individuals demonstrated a decrease in inflammatory and oxidative responses, reduction of DNA damage and apoptosis in peripheral blood leucocytes (133). In another study, probiotic stains plus selenium supplementation resulted in a better cognitive score in AD patients. Moreover, probiotics enhanced the selenium effect on the reduction of high sensitive C-reactive protein and an increase in total antioxidant capacity and the glutathione level (134).

## FECAL MICROBIOTA TRANSPLANTATION

FMT is a transfer of fecal material from a healthy donor into the patient's gastrointestinal tract. This procedure is a powerful means of regulating the GM and is being actively studied for many diseases at the moment. Despite this approach being promising, we have very limited data on the use of this method for AD (135). FMT from WT mice into ADLP<sup>APT</sup> mice improved intestinal barrier integrity and decreased the formation of amyloid plaques and neurofibrillary tangles in animal brains (136). In another AD mouse model FMT from healthy individual

following FMT from AD patients decreased the expression of pro-inflammatory cytokines in blood and hippocampus and improved cognitive ability of animals (55). One case study reported long-term improvement in the mental acuity of 82-year-old patient after FMT (137).

## CONCLUSION

Existing evidence suggests that dietary lifestyle changes may affect cognitive function. Certain nutrients appear to be beneficial in maintaining neuronal homeostasis and slowing cognitive decline. Along with it, the most convincing evidence was reported for whole-diet approaches such as MeD, DASH, and MIND. One of the key roles in the diet impact on cognitive performance and AD risk belongs to the composition and functional activity of the GM. It has now been shown that microbiota affects brain functions through various metabolites with potentially positive or, conversely, toxic properties. Moreover, by converting food precursors, the intestinal flora regulates the availability of nutrients important for cognition. It seems that the GM involvement in the SCFA and polyphenols metabolism may contribute to the cognitive promotion effect of healthy dietary patterns. In addition, the use of probiotics can be part of a comprehensive approach to delay neurodegeneration. However, for a long-term GM modification, a whole-diet may have advantages over nutrients alone or in combination. Overall, the GM is an important factor to be considered in future research of dietary effects on cognitive function. Thus, the underlying mechanisms of interaction between nutrition, microbiota, and the host require additional studies for developing effective dietary strategies within integrated AD prevention and control.

## AUTHOR CONTRIBUTIONS

AV conceptualized the structure and wrote the first draft. MR, AK, and VK co-wrote the first draft. MR edited the final version of the manuscript. All authors approved the final version of the manuscript.

## REFERENCES

1. Alzheimer's Disease International. *World Alzheimer Report 2019: Attitudes to dementia*. London: Alzheimer's Disease International (2019). p. 166. Available online at: <https://www.alzint.org/u/WorldAlzheimerReport2019.pdf> (accessed May 2, 2021).
2. El-Hayek YH, Wiley RE, Khoury CP, Daya RP, Ballard C, Evans AR, et al. Tip of the Iceberg: assessing the global socioeconomic costs of Alzheimer's disease and related dementias and strategic implications for stakeholders. *J Alzheimers Dis.* (2019) 70:323–41. doi: 10.3233/JAD-190426
3. Wimo A, Guerchet M, Ali GC, Wu YT, Prina AM, Winblad B, et al. The worldwide costs of dementia 2015 and comparisons with 2010. *Alzheimers Dement.* (2017) 13:1–7. doi: 10.1016/j.jalz.2016.07.150
4. Vauzour D, Camprubi-Robles M, Miquel-Kergoat S, Andres-Lacueva C, Bánáti D, Barberger-Gateau P, et al. Nutrition for the ageing brain: towards evidence for an optimal diet. *Ageing Res Rev.* (2017) 35:222–40. doi: 10.1016/j.arr.2016.09.010
5. Scarmeas N, Anastasiou CA, Yannakoulia M. Nutrition and prevention of cognitive impairment. *Lancet Neurol.* (2018) 7:1006–15. doi: 10.1016/S1474-4422(18)30338-7
6. Pistollato F, Sumalla Cano S, Elio I, Masias Vergara M, Giampieri E, Battino M. Role of gut microbiota and nutrients in amyloid formation and pathogenesis of Alzheimer disease. *Nutr Rev.* (2016) 74:624–34. doi: 10.1093/nutrit/nuw023
7. Pellegrini C, Antonioli L, Colucci R, Blandizzi C, Fornai M. Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases? *Acta Neuropathol.* (2018) 136:345–61. doi: 10.1007/s00401-018-1856-5
8. Sampson TR, Mazmanian SK. Control of brain development, function, and behavior by the microbiome. *Cell Host Microbe.* (2015) 17:565–76. doi: 10.1016/j.chom.2015.04.011
9. Cerovic M, Forloni G, Balducci C. Neuroinflammation and the gut microbiota: possible alternative therapeutic targets to counteract Alzheimer's disease? *Front Aging Neurosci.* (2019) 11:284. doi: 10.3389/fnagi.2019.00284

10. Shabbir U, Arshad MS, Sameen A, Oh DH. Crosstalk between gut and brain in Alzheimer's disease: the role of gut microbiota modulation strategies. *Nutrients*. (2021) 13:690. doi: 10.3390/nu13020690
11. García-Montero C, Fraile-Martínez O, Gómez-Lahoz AM, Pekarek L, Castellanos AJ, Noguerales-Fraguas F, et al. Nutritional components in Western diet versus Mediterranean diet at the gut microbiota-immune system interplay. Implications for health and disease. *Nutrients*. (2021) 13:699. doi: 10.3390/nu13020699
12. Solfrizzi V, Custodero C, Lozupone M, Imbimbo BP, Valiani V, Agosti P, et al. Relationships of dietary patterns, foods, and micro- and macronutrients with Alzheimer's disease and late-life cognitive disorders: a systematic review. *J Alzheimers Dis*. (2017) 59:815–49. doi: 10.3233/JAD-170248
13. Moore K, Hughes CF, Ward M, Hoey L, McNulty H. Diet, nutrition and the ageing brain: current evidence and new directions. *Proc Nutr Soc*. (2018) 77:152–63. doi: 10.1017/S0029665117004177
14. Trichopoulou A, Kyrozi A, Rossi M, Katsoulis M, Trichopoulos D, La Vecchia C, et al. Mediterranean diet and cognitive decline over time in an elderly Mediterranean population. *Eur J Nutr*. (2015) 54:1311–21. doi: 10.1007/s00394-014-0811-z
15. Staubo SC, Aakre JA, Vemuri P, Syrjanen JA, Mielke MM, Geda YE, et al. Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. *Alzheimers Dement*. (2017) 13:168–77. doi: 10.1016/j.jalz.2016.06.2359
16. Dong L, Xiao R, Cai C, Xu Z, Wang S, Pan L, et al. Diet, lifestyle and cognitive function in old Chinese adults. *Arch Gerontol Geriatr*. (2016) 63:36–42. doi: 10.1016/j.archger.2015.12.003
17. Oliphant K, Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. *Microbiome*. (2019) 7:91. doi: 10.1186/s40168-019-0704-8
18. Gu Y, Brickman AM, Stern Y, Habeck CG, Razlighi QR, Luchsinger JA, et al. Mediterranean diet and brain structure in a multiethnic elderly cohort. *Neurology*. (2015) 85:1744–51. doi: 10.1212/WNL.0000000000002121
19. Qin B, Plassman BL, Edwards LJ, Popkin BM, Adair LS, Mendez MA. Fish intake is associated with slower cognitive decline in Chinese older adults. *J Nutr*. (2014) 144:1579–85. doi: 10.3945/jn.114.193854
20. Fischer K, Melo van Lent D, Wolfsgruber S, Weinhold L, Kleineidam L, Bickel H, et al. Prospective associations between single foods, Alzheimer's dementia and memory decline in the elderly. *Nutrients*. (2018) 10:852. doi: 10.3390/nu10070852
21. Bakre AT, Chen R, Khutan R, Wei L, Smith T, Qin G, et al. Association between fish consumption and risk of dementia: a new study from China and a systematic literature review and meta-analysis. *Public Health Nutr*. (2018) 21:1921–32. doi: 10.1017/S136898001800037X
22. Fiala M, Kooij G, Wagner K, Hammock B, Pellegrini M. Modulation of innate immunity of patients with Alzheimer's disease by omega-3 fatty acids. *FASEB J*. (2017) 31:3229–39. doi: 10.1096/fj.201700065R
23. Joffre C, Rey C, Layé S. N-3 polyunsaturated fatty acids and the resolution of neuroinflammation. *Front Pharmacol*. (2019) 10:1022. doi: 10.3389/fphar.2019.01022
24. Morgese MG, Schiavone S, Maffione AB, Tucci P, Trabace L. Depressive-like phenotype evoked by lifelong nutritional omega-3 deficiency in female rats: crosstalk among kynurenine, Toll-like receptors and amyloid beta oligomers. *Brain Behav Immun*. (2020) 87:444–54. doi: 10.1016/j.bbi.2020.01.015
25. Fonteh AN, Cipolla M, Chiang AJ, Edminster SP, Arakaki X, Harrington MG. Polyunsaturated fatty acid composition of cerebrospinal fluid fractions shows their contribution to cognitive resilience of a pre-symptomatic Alzheimer's disease cohort. *Front Physiol*. (2020) 11:83. doi: 10.3389/fphys.2020.00083
26. Melo van Lent D, Egert S, Wolfsgruber S, Kleineidam L, Weinhold L, Wagner-Thelen H, et al. Eicosapentaenoic acid is associated with decreased incidence of Alzheimer's dementia in the oldest old. *Nutrients*. (2021) 13:461. doi: 10.3390/nu13020461
27. Kaliannan K, Wang B, Li XY, Kim KJ, Kang JX. A host-microbiome interaction mediates the opposing effects of omega-6 and omega-3 fatty acids on metabolic endotoxemia. *Sci Rep*. (2015) 5:11276. doi: 10.1038/srep11276
28. Cao W, Wang C, Chin Y, Chen X, Gao Y, Yuan S, et al. DHA-phospholipids (DHA-PL) and EPA-phospholipids (EPA-PL) prevent intestinal dysfunction induced by chronic stress. *Food Funct*. (2019) 10:277–88. doi: 10.1039/C8FO01404C
29. Robertson RC, Seira Oriach C, Murphy K, Moloney GM, Cryan JF, Dinan TG, et al. Omega-3 polyunsaturated fatty acids critically regulate behaviour and gut microbiota development in adolescence and adulthood. *Brain Behav Immun*. (2017) 59:21–37. doi: 10.1016/j.bbi.2016.07.145
30. Rangel-Huerta OD, Gil A. Effect of omega-3 fatty acids on cognition: an updated systematic review of randomized clinical trials. *Nutr Rev*. (2018) 76:1–20. doi: 10.1093/nutrit/nux064
31. Ngabirano L, Samieri C, Fear C, Gabelle A, Artero S, Duflos C, et al. Intake of meat, fish, fruits, and vegetables and long-term risk of dementia and Alzheimer's disease. *J Alzheimers Dis*. (2019) 68:711–22. doi: 10.3233/JAD-180919
32. Zhang H, Hardie L, Bawajeeh AO, Cade J. Meat consumption, cognitive function and disorders: a systematic review with narrative synthesis and meta-analysis. *Nutrients*. (2020) 12:1528. doi: 10.3390/nu12051528
33. Lee J, Fu Z, Chung M, Jang DJ, Lee HJ. Role of milk and dairy intake in cognitive function in older adults: a systematic review and meta-analysis. *Nutr J*. (2018) 17:82. doi: 10.1186/s12937-018-0387-1
34. Bermejo-Pareja F, Ciudad-Cabañas MJ, Llamas-Velasco S, Tapias-Merino E, Hernández Gallego J, Hernández-Cabria M, et al. Is milk and dairy intake a preventive factor for elderly cognition (dementia and Alzheimer's)? A quality review of cohort surveys. *Nutr Rev*. (2020) 14:nuaa045. doi: 10.1093/nutrit/nuaa045
35. Petruski-Ivleva N, Kucharska-Newton A, Palta P, Couper D, Meyer K, Graff M, et al. Milk intake at midlife and cognitive decline over 20 years. The Atherosclerosis Risk in Communities (ARIC) Study. *Nutrients*. (2017) 9:1134. doi: 10.3390/nu9101134
36. Ozawa M, Ohara T, Ninomiya T, Hata J, Yoshida D, Mukai N, et al. Milk and dairy consumption and risk of dementia in an elderly Japanese population: the Hisayama Study. *J Am Geriatr Soc*. (2014) 62:1224–30. doi: 10.1111/jgs.12887
37. Shwe T, Pratchayasakul W, Chattapakorn N, Chattapakorn SC. Role of D-galactose-induced brain aging and its potential used for therapeutic interventions. *Exp Gerontol*. (2018) 101:13–36. doi: 10.1016/j.exger.2017.10.029
38. Nimgampalle M, Kuna Y. Anti-Alzheimer properties of probiotic, *Lactobacillus plantarum* MTCC 1325 in Alzheimer's disease induced albino rats. *J Clin Diagn Res*. (2017) 11:KC01–5. doi: 10.7860/JCDR/2017/26106.10428
39. Banji OJ, Banji D, Ch K. Curcumin and hesperidin improve cognition by suppressing mitochondrial dysfunction and apoptosis induced by D-galactose in rat brain. *Food Chem Toxicol*. (2014) 74:51–9. doi: 10.1016/j.fct.2014.08.020
40. Wang C, Cai Z, Wang W, Wei M, Si X, Shang Y, et al. Piperine regulates glycogen synthase kinase-3 $\beta$ -related signaling and attenuates cognitive decline in D-galactose-induced aging mouse model. *J Nutr Biochem*. (2020) 75:108261. doi: 10.1016/j.jnutbio.2019.108261
41. Tsigoulis G, Judd S, Letter AJ, Alexandrov AV, Howard G, Nahab F, et al. Adherence to a Mediterranean diet and risk of incident cognitive impairment. *Neurology*. (2013) 80:1684–92. doi: 10.1212/WNL.0b013e3182904f69
42. van den Brink AC, Brouwer-Brolsma EM, Berendsen AAM, van de Rest O. The mediterranean, dietary approaches to stop hypertension (DASH), and mediterranean-DASH intervention for neurodegenerative delay (mind) diets are associated with less cognitive decline and a lower risk of Alzheimer's disease—a review. *Adv Nutr*. (2019) 10:1040–65. doi: 10.1093/advances/nmz054
43. Solfrizzi V, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Vendemiale G, et al. Dietary fatty acids in dementia and predementia syndromes: epidemiological evidence and possible underlying mechanisms. *Ageing Res Rev*. (2010) 9:184–99. doi: 10.1016/j.arr.2009.07.005
44. Morris MC, Tangney CC, Wang Y, Sacks FM, Barnes LL, Bennett DA, et al. MIND diet slows cognitive decline with aging. *Alzheimers Dement*. (2015) 11:1015–22. doi: 10.1016/j.jalz.2015.04.011
45. Morris MC, Tangney CC, Wang Y, Sacks FM, Bennett DA, Aggarwal NT. MIND diet associated with reduced incidence of Alzheimer's disease. *Alzheimers Dement*. (2015) 11:1007–14. doi: 10.1016/j.jalz.2014.11.009

46. Hosking DE, Eramudugolla R, Cherbuin N, Anstey KJ. MIND not Mediterranean diet related to 12-year incidence of cognitive impairment in an Australian longitudinal cohort study. *Alzheimers Dement.* (2019) 15:581–89. doi: 10.1016/j.jalz.2018.12.011
47. Godos J, Rapisarda G, Marventano S, Galvano F, Mistretta A, Grosso G. Association between polyphenol intake and adherence to the Mediterranean diet in Sicily, southern Italy. *NFS Journal.* (2017) 8:1–7. doi: 10.1016/j.nfs.2017.06.001
48. Zhang T, Han X, Zhang X, Chen Z, Mi Y, Gou X. Dietary fatty acid factors in Alzheimer's disease: a review. *J Alzheimers Dis.* (2020) 78:887–904. doi: 10.3233/JAD-200558
49. Jiang C, Li G, Huang P, Liu Z, Zhao B. The gut microbiota and Alzheimer's disease. *J Alzheimers Dis.* (2017) 58:1–15. doi: 10.3233/JAD-161141
50. Askarova S, Umbayev B, Masoud AR, Kaiyrylkyzy A, Safarova Y, Tsoy A, et al. The links between the gut microbiome, aging, modern lifestyle and Alzheimer's disease. *Front Cell Infect Microbiol.* (2020) 10:104. doi: 10.3389/fcimb.2020.00104
51. Le Page A, Dupuis G, Frost EH, Larbi A, Pawelec G, Witkowski JM, et al. Role of the peripheral innate immune system in the development of Alzheimer's disease. *Exp Gerontol.* (2018) 107:59–66. doi: 10.1016/j.exger.2017.12.019
52. Spielman LJ, Gibson DL, Klegeris A. Unhealthy gut, unhealthy brain: the role of the intestinal microbiota in neurodegenerative diseases. *Neurochem Int.* (2018) 120:149–63. doi: 10.1016/j.neuint.2018.08.005
53. Lin L, Zheng LJ, Zhang LJ. Neuroinflammation, gut microbiome, and Alzheimer's disease. *Mol Neurobiol.* (2018) 55:8243–50. doi: 10.1007/s12035-018-0983-2
54. Kowalski K, Mulak A. Brain-gut-microbiota axis in Alzheimer's disease. *J Neurogastroenterol Motil.* (2019) 25:48–60. doi: 10.5056/jnm18087
55. Shen H, Guan Q, Zhang X, Yuan C, Tan Z, Zhai L, et al. New mechanism of neuroinflammation in Alzheimer's disease: the activation of NLRP3 inflammasome mediated by gut microbiota. *Prog Neuropsychopharmacol Biol Psychiatry.* (2020) 100:109884. doi: 10.1016/j.pnpbp.2020.109884
56. Li D, Ke Y, Zhan R, Liu C, Zhao M, Zeng A, et al. Trimethylamine-N-oxide promotes brain aging and cognitive impairment in mice. *Aging Cell.* (2018) 17:e12768. doi: 10.1111/ace1.12768
57. Vogt NM, Romano KA, Darst BF, Engelman CD, Johnson SC, Carlsson CM, et al. The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease. *Alzheimers Res Ther.* (2018) 10:124. doi: 10.1186/s13195-018-0451-2
58. Nho K, Kueider-Paisley A, MahmoudianDehkordi S, Arnold M, Risacher SL, Louie G, et al. Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium. Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: relationship to neuroimaging and CSF biomarkers. *Alzheimers Dement.* (2019) 15:232–44. doi: 10.1101/284141
59. MahmoudianDehkordi S, Arnold M, Nho K, Ahmad S, Jia W, Xie G, et al. Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—an emerging role for gut microbiome. *Alzheimers Dement.* (2019) 15:76–92. doi: 10.1016/j.jalz.2018.07.217
60. Haran JP, Bhattarai SK, Foley SE, Dutta P, Ward DV, Bucci V, et al. Alzheimer's disease microbiome is associated with dysregulation of the anti-inflammatory P-glycoprotein pathway. *mBio.* (2019) 10:e00632–19. doi: 10.1128/mBio.00632-19
61. Garcez ML, Jacobs KR, Guillemin GJ. Microbiota alterations in Alzheimer's disease: involvement of the kynurenine pathway and inflammation. *Neurotox Res.* (2019) 36:424–36. doi: 10.1007/s12640-019-00057-3
62. Zhao Y, Lukiw WJ. Microbiome-mediated upregulation of microRNA-146a in sporadic Alzheimer's disease. *Front Neurol.* (2018) 9:145. doi: 10.3389/fneur.2018.00145
63. Friedland RP, Chapman MR. The role of microbial amyloid in neurodegeneration. *PLoS Pathog.* (2017) 13:e1006654. doi: 10.1371/journal.ppat.1006654
64. Chen SG, Stribinskis V, Rane MJ, Demuth DR, Gozal E, Roberts AM, et al. Exposure to the functional bacterial amyloid protein curli enhances alpha-synuclein aggregation in aged fischer 344 rats and *Caenorhabditis elegans*. *Sci Rep.* (2016) 6:34477. doi: 10.1038/srep34477
65. Zhan G, Yang N, Li S, Huang N, Fang X, Zhang J, et al. Abnormal gut microbiota composition contributes to cognitive dysfunction in SAMP8 mice. *Aging (Albany NY).* (2018) 10:1257–67. doi: 10.18632/aging.101464
66. Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, et al. Gut microbiome alterations in Alzheimer's disease. *Sci Rep.* (2017) 7:13537. doi: 10.1038/s41598-017-13601-y
67. Zhuang ZQ, Shen LL, Li WW, Fu X, Zeng F, Gui L, et al. Gut microbiota is altered in patients with Alzheimer's disease. *J Alzheimers Dis.* (2018) 63:1337–46. doi: 10.3233/JAD-180176
68. Hou M, Xu G, Ran M, Luo W, Wang H. APOE-ε4 carrier status and gut microbiota dysbiosis in patients with Alzheimer disease. *Front Neurosci.* (2021) 15:619051. doi: 10.3389/fnins.2021.619051
69. Panza F, Lozupone M, Solfrizzi V, Watling M, Imbimbo BP. Time to test antibacterial therapy in Alzheimer's disease. *Brain.* (2019) 142:2905–29. doi: 10.1093/brain/awz244
70. Ticinesi A, Nouvenne A, Tana C, Prati B, Meschi T. Gut microbiota and microbiota-related metabolites as possible biomarkers of cognitive aging. *Adv Exp Med Biol.* (2019) 1178:129–54. doi: 10.1007/978-3-030-25650-0\_8
71. Liu P, Wu L, Peng G, Han Y, Tang R, Ge J, et al. Altered microbiomes distinguish Alzheimer's disease from amnesic mild cognitive impairment and health in a Chinese cohort. *Brain Behav Immun.* (2019) 80:633–43. doi: 10.1016/j.bbi.2019.05.008
72. Wu L, Han Y, Zheng Z, Peng G, Liu P, Yue S, et al. Altered gut microbial metabolites in amnesic mild cognitive impairment and Alzheimer's disease: signals in host-microbe interplay. *Nutrients.* (2021) 13:228. doi: 10.3390/nu13010228
73. Whitley L, Chappell KE, D'Hondt E, Lewis MR, Jiménez B, Snowden SG, et al. Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's disease. *Alzheimers Res Ther.* (2021) 13:20. doi: 10.1186/s13195-020-00741-z
74. Flint HJ. The impact of nutrition on the human microbiome. *Nutr Rev.* (2012) 70:S10–3. doi: 10.1111/j.1753-4887.2012.00499.x
75. Quercia S, Candela M, Giuliani C, Turroni S, Luiselli D, Rampelli S, et al. From lifetime to evolution: timescales of human gut microbiota adaptation. *Front Microbiol.* (2014) 5:587. doi: 10.3389/fmicb.2014.00587
76. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. *Cell.* (2016) 165:1332–45. doi: 10.1016/j.cell.2016.05.041
77. Blaaq EE, Canfora EE, Theis S, Frost G, Groen AK, Mithieux G, et al. Short chain fatty acids in human gut and metabolic health. *Benef Microbes.* (2020) 11:411–55. doi: 10.3920/BM2020.0057
78. Braniste V, Al-Asmakh M, Kowal C, Anuar F, Abbaspour A, Tóth M, et al. The gut microbiota influences blood-brain barrier permeability in mice. *Sci Transl Med.* (2014) 6:263ra158. doi: 10.1126/scitranslmed.3009759
79. Corrêa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MA. Regulation of immune cell function by short-chain fatty acids. *Clin Transl Immunology.* (2016) 5:e73. doi: 10.1038/cti.2016.17
80. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. *Nat Rev Gastroenterol Hepatol.* (2019) 16:461–78. doi: 10.1038/s41575-019-0157-3
81. Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. *Front Endocrinol (Lausanne).* (2020) 11:25. doi: 10.3389/fendo.2020.00025
82. Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. *Proc Natl Acad Sci USA.* (2008) 105:16767–72. doi: 10.1073/pnas.0808567105
83. Soliman ML, Rosenberger TA. Acetate supplementation increases brain histone acetylation and inhibits histone deacetylase activity and expression. *Mol Cell Biochem.* (2011) 352:173–80. doi: 10.1007/s11010-011-0751-3
84. Vaiserman AM, Koliada AK, Koshel' NM, Simonenko AV, Pasiukova EG. [Effect of the histone deacetylase inhibitor sodium butyrate on the viability and life span in *Drosophila melanogaster*]. *Adv Gerontol.* (2012) 25:126–31. [in Russian]

85. Wang P, Zhang Y, Gong Y, Yang R, Chen Z, Hu W, et al. Sodium butyrate triggers a functional elongation of microglial process via Akt-small RhoGTPase activation and HDACs inhibition. *Neurobiol Dis.* (2018) 111:12–25. doi: 10.1016/j.nbd.2017.12.006
86. Ho L, Ono K, Tsuji M, Mazzola P, Singh R, Pasinetti GM. Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimer's disease-type beta-amyloid neuropathological mechanisms. *Expert Rev Neurother.* (2018) 18:83–90. doi: 10.1080/14737175.2018.1400909
87. Hoffman JD, Yanckello LM, Chlipala G, Hammond TC, McCulloch SD, Parikh I, et al. Dietary inulin alters the gut microbiome, enhances systemic metabolism and reduces neuroinflammation in an APOE4 mouse model. *PLoS ONE.* (2019) 14:e0221828. doi: 10.1371/journal.pone.0221828
88. Colombo AV, Sadler RK, Llovera G, Singh V, Roth S, Heindl S, et al. Microbiota-derived short chain fatty acids modulate microglia and promote A $\beta$  plaque deposition. *Elife.* (2021) 10:e59826. doi: 10.7554/eLife.59826
89. Marizzoni M, Cattaneo A, Mirabelli P, Festari C, Lopizzo N, Nicolosi V, et al. Short-chain fatty acids and lipopolysaccharide as mediators between gut dysbiosis and amyloid pathology in Alzheimer's disease. *J Alzheimers Dis.* (2020) 78:683–97. doi: 10.3233/JAD-200306
90. Pacheco-Ordaz R, Wall-Medrano A, Goñi MG, Ramos-Clamont-Montfort G, Ayala-Zavala JF, González-Aguilar GA. Effect of phenolic compounds on the growth of selected probiotic and pathogenic bacteria. *Lett Appl Microbiol.* (2018) 66:25–31. doi: 10.1111/lam.12814
91. Moreno-Indias I, Sánchez-Alcoholado L, Pérez-Martínez P, Andrés-Lacueva C, Cardona F, Tinahones F, et al. Red wine polyphenols modulate fecal microbiota and reduce markers of the metabolic syndrome in obese patients. *Food Funct.* (2016) 7:1775–87. doi: 10.1039/C5FO00886G
92. Braune A, Blaut M. Bacterial species involved in the conversion of dietary flavonoids in the human gut. *Gut Microbes.* (2016) 7:216–34. doi: 10.1080/19490976.2016.1158395
93. Marín L, Miguélez EM, Villar CJ, Lombó F. Bioavailability of dietary polyphenols and gut microbiota metabolism: antimicrobial properties. *Biomed Res Int.* (2015) 2015:905215. doi: 10.1155/2015/905215
94. Shishtar E, Rogers GT, Blumberg JB, Au R, Jacques PF. Long-term dietary flavonoid intake and risk of Alzheimer disease and related dementias in the Framingham Offspring Cohort. *Am J Clin Nutr.* (2020) 112:343–53. doi: 10.1093/ajcn/nqaa079
95. Cho I, Song HO, Cho JH. Flavonoids mitigate neurodegeneration in aged *Caenorhabditis elegans* by mitochondrial uncoupling. *Food Sci Nutr.* (2020) 8:6633–42. doi: 10.1002/fsn3.1956
96. Khan H, Ullah H, Aschner M, Cheang WS, Akkol EK. Neuroprotective effects of quercetin in Alzheimer's disease. *Biomolecules.* (2019) 10:59. doi: 10.3390/biom10010059
97. Gomes BAQ, Silva JPB, Romeiro CFR, Dos Santos SM, Rodrigues CA, Gonçalves PR, et al. Neuroprotective mechanisms of resveratrol in Alzheimer's disease: role of SIRT1. *Oxid Med Cell Longev.* (2018) 2018:8152373. doi: 10.1155/2018/8152373
98. Mori T, Koyama N, Yokoo T, Segawa T, Maeda M, Sawmiller D, et al. Gallic acid is a dual  $\alpha/\beta$ -secretase modulator that reverses cognitive impairment and remediates pathology in Alzheimer mice. *J Biol Chem.* (2020) 295:16251–66. doi: 10.1074/jbc.RA119.012330
99. Bernardi S, Del Bo' C, Marino M, Gargari G, Cherubini A, Andrés-Lacueva C, et al. Polyphenols and intestinal permeability: rationale and future perspectives. *J Agric Food Chem.* (2020) 68:1816–29. doi: 10.1021/acs.jafc.9b02283
100. Del Bo' C, Bernardi S, Cherubini A, Porrini M, Gargari G, Hidalgo-Liberona N, et al. A polyphenol-rich dietary pattern improves intestinal permeability, evaluated as serum zonulin levels, in older subjects: the MaPLE randomised controlled trial. *Clin Nutr.* (2021) 40:3006–18. doi: 10.1016/j.clnu.2020.12.014
101. Koudoufio M, Desjardins Y, Feldman F, Spahis S, Delvin E, Levy E. Insight into polyphenol and gut microbiota crosstalk: are their metabolites the key to understand protective effects against metabolic disorders? *Antioxidants (Basel).* (2020) 9:982. doi: 10.3390/antiox9100982
102. Gutiérrez-Díaz I, Fernández-Navarro T, Sánchez B, Margolles A, González S. Mediterranean diet and faecal microbiota: a transversal study. *Food Funct.* (2016) 7:2347–56. doi: 10.1039/C6FO00105J
103. Papandreou C, Moré M, Bellamine A. Trimethylamine N-oxide in relation to cardiometabolic health-cause or effect? *Nutrients.* (2020) 12:1330. doi: 10.3390/nu12051330
104. Nowiński A, Ufnal M. Trimethylamine N-oxide: a harmful, protective or diagnostic marker in lifestyle diseases? *Nutrition.* (2018) 46:7–12. doi: 10.1016/j.nut.2017.08.001
105. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. *Int Clin Psychopharmacol.* (2003) 18:61–71. doi: 10.1097/00004850-200303000-00001
106. Eussen SJ, Ueland PM, Clarke R, Blom HJ, Hoefnagels WH, van Staveren WA, et al. The association of betaine, homocysteine and related metabolites with cognitive function in Dutch elderly people. *Br J Nutr.* (2007) 98:960–8. doi: 10.1017/S0007114507750912
107. Blusztajn JK, Slack BE, Mellott TJ. Neuroprotective actions of dietary choline. *Nutrients.* (2017) 9:815. doi: 10.3390/nu9080815
108. Velazquez R, Ferreira E, Knowles S, Fux C, Rodin A, Winslow W, et al. Lifelong choline supplementation ameliorates Alzheimer's disease pathology and associated cognitive deficits by attenuating microglia activation. *Aging Cell.* (2019) 18:e13037. doi: 10.1111/acer.13037
109. Kepka A, Ochocimska A, Borzym-Kluczyk M, Skorupa E, Stasiewicz-Jarocka B, Chojnowska S, et al. Preventive role of l-carnitine and balanced diet in Alzheimer's disease. *Nutrients.* (2020) 12:1987. doi: 10.3390/nu12071987
110. Ibi D, Hirashima K, Kojima Y, Sumiya K, Kondo S, Yamamoto M, et al. Preventive effects of continuous betaine intake on cognitive impairment and aberrant gene expression in hippocampus of 3xTg mouse model of Alzheimer's disease. *J Alzheimers Dis.* (2021) 79:639–52. doi: 10.3233/JAD-200972
111. Simó C, García-Cañas V. Dietary bioactive ingredients to modulate the gut microbiota-derived metabolite TMAO. New opportunities for functional food development. *Food Funct.* (2020) 11:6745–76. doi: 10.1039/D0FO01237H
112. Berge RK, Ramsvik MS, Bohov P, Svardal A, Nordrehaug JE, Rostrup E, et al. Krill oil reduces plasma triacylglycerol level and improves related lipoprotein particle concentration, fatty acid composition and redox status in healthy young adults - a pilot study. *Lipids Health Dis.* (2015) 14:163. doi: 10.1186/s12944-015-0162-7
113. Lemos BS, Medina-Vera I, Malysheva OV, Caudill MA, Fernandez ML. Effects of egg consumption and choline supplementation on plasma choline and trimethylamine-N-oxide in a young population. *J Am Coll Nutr.* (2018) 37:716–23. doi: 10.1080/07315724.2018.1466213
114. Griffin LE, Djuric Z, Angioletta CJ, Mitchell CM, Baugh ME, Davy KP, et al. A Mediterranean diet does not alter plasma trimethylamine N-oxide concentrations in healthy adults at risk for colon cancer. *Food Funct.* (2019) 10:2138–47. doi: 10.1039/C9FO00333A
115. Wang Z, Bergeron N, Levison BS, Li XS, Chiu S, Jia X, et al. Impact of chronic dietary red meat, white meat, or non-meat protein on trimethylamine N-oxide metabolism and renal excretion in healthy men and women. *Eur Heart J.* (2019) 40:583–94. doi: 10.1093/eurheartj/ehy799
116. Romano KA, Vivas EI, Amador-Noguez D, Rey FE. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. *mBio.* (2015) 6:e02481. doi: 10.1128/mBio.02481-14
117. Cattaneo A, Cattane N, Galluzzi S, Provasi S, Lopizzo N, Festari C, et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. *Neurobiol Aging.* (2017) 49:60–8. doi: 10.1016/j.neurobiolaging.2016.08.019
118. Cho CE, Tausuwan S, Malysheva OV, Bender E, Tulchinsky NF, Yan J, et al. Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: a randomized controlled trial. *Mol Nutr Food Res.* (2017) 61:1600324. doi: 10.1002/mnfr.201770016
119. Wu WK, Chen CC, Liu PY, Panyod S, Liao BY, Chen PC, et al. Identification of TMAO-producer phenotype and host-diet-gut dysbiosis by carnitine challenge test in human and germ-free mice. *Gut.* (2019) 68:1439–49. doi: 10.1136/gutjnl-2018-317155

120. Chung SJ, Rim JH, Ji D, Lee S, Yoo HS, Jung JH, et al. Gut microbiota-derived metabolite trimethylamine N-oxide as a biomarker in early Parkinson's disease. *Nutrition*. (2021) 83:111090. doi: 10.1016/j.nut.2020.111090
121. Chen L, Chen Y, Zhao M, Zheng L, Fan D. Changes in the concentrations of trimethylamine N-oxide (TMAO) and its precursors in patients with amyotrophic lateral sclerosis. *Sci Rep*. (2020) 10:15198. doi: 10.1038/s41598-020-72184-3
122. Pluta R, Ułamek-Kozioł M, Januszewski S, Czuczwar SJ. Gut microbiota and pro/prebiotics in Alzheimer's disease. *Aging (Albany NY)*. (2020) 12:5539–50. doi: 10.18632/aging.102930
123. Arora K, Green M, Prakash S. The microbiome and Alzheimer's disease: potential and limitations of prebiotic, synbiotic, and probiotic formulations. *Front Bioeng Biotechnol*. (2020) 8:537847. doi: 10.3389/fbioe.2020.537847
124. Liu Q, Xi Y, Wang Q, Liu J, Li P, Meng X, et al. Mannan oligosaccharide attenuates cognitive and behavioral disorders in the 5xFAD Alzheimer's disease mouse model via regulating the gut microbiota-brain axis. *Brain Behav Immun*. (2021) 95:330–43. doi: 10.1016/j.bbi.2021.04.005
125. Xin Y, Diling C, Jian Y, Ting L, Guoyan H, Hualun L, et al. Effects of oligosaccharides from *Morinda officinalis* on gut microbiota and metabolome of APP/PS1 transgenic mice. *Front Neurol*. (2018) 9:412. doi: 10.3389/fneur.2018.00412
126. Han D, Li Z, Liu T, Yang N, Li Y, He J, et al. Prebiotics regulation of intestinal microbiota attenuates cognitive dysfunction induced by surgery stimulation in APP/PS1 mice. *Aging Dis*. (2020) 11:1029–45. doi: 10.14336/AD.2020.0106
127. Xu M, Mo X, Huang H, Chen X, Liu H, Peng Z, et al. Yeast  $\beta$ -glucan alleviates cognitive deficit by regulating gut microbiota and metabolites in A $\beta$ 1-42-induced AD-like mice. *Int J Biol Macromol*. (2020) 161:258–70. doi: 10.1016/j.ijbiomac.2020.05.180
128. Lee YS, Lai DM, Huang HJ, Lee-Chen GJ, Chang CH, Hsieh-Li HM, et al. Prebiotic lactulose ameliorates the cognitive deficit in Alzheimer's disease mouse model through macroautophagy and chaperone-mediated autophagy pathways. *J Agric Food Chem*. (2021) 69:2422–37. doi: 10.1021/acs.jafc.0c07327
129. Kobayashi Y, Sugahara H, Shimada K, Mitsuyama E, Kuhara T, Yasuoka A, et al. Therapeutic potential of *Bifidobacterium breve* strain A1 for preventing cognitive impairment in Alzheimer's disease. *Sci Rep*. (2017) 7:13510. doi: 10.1038/s41598-017-13368-2
130. Kobayashi Y, Kinoshita T, Matsumoto A, Yoshino K, Saito I, Xiao JZ. *Bifidobacterium breve* A1 supplementation improved cognitive decline in older adults with mild cognitive impairment: an open-label, single-arm study. *J Prev Alzheimers Dis*. (2019) 6:70–5. doi: 10.14283/jpad.2018.32
131. Xiao J, Katsumata N, Bernier E, Ohno K, Yamauchi Y, Odamaki T, et al. Probiotic *Bifidobacterium breve* in improving cognitive functions of older adults with suspected mild cognitive impairment: a randomized, double-blind, placebo-controlled trial. *J Alzheimers Dis*. (2020) 77:139–47. doi: 10.3233/JAD-200488
132. Leblhuber F, Steiner K, Schuetz B, Fuchs D, Gostner JM. Probiotic supplementation in patients with Alzheimer's dementia - an explorative intervention study. *Curr Alzheimer Res*. (2018) 15:1106–13. doi: 10.2174/1389200219666180813144834
133. Ton AMM, Campagnaro BP, Alves GA, Aires R, Côco LZ, Arpini CM, et al. Oxidative stress and dementia in Alzheimer's patients: effects of synbiotic supplementation. *Oxid Med Cell Longev*. (2020) 2020:2638703. doi: 10.1155/2020/2638703
134. Tamtaji OR, Heidari-Soureshjani R, Mirhosseini N, Kouchaki E, Bahmani F, Aghadavod E, et al. Probiotic and selenium co-supplementation, and the effects on clinical, metabolic and genetic status in Alzheimer's disease: a randomized, double-blind, controlled trial. *Clin Nutr*. (2019) 38:2569–75. doi: 10.1016/j.clnu.2018.11.034
135. Vendrik KEW, Ooijevaar RE, de Jong PRC, Laman JD, van Oosten BW, van Hilten JJ, et al. Fecal microbiota transplantation in neurological disorders. *Front Cell Infect Microbiol*. (2020) 10:98. doi: 10.3389/fcimb.2020.00098
136. Kim MS, Kim Y, Choi H, Kim W, Park S, Lee D, et al. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer's disease animal model. *Gut*. (2020) 69:283–94. doi: 10.1136/gutjnl-2018-317431
137. Hazan S. Rapid improvement in Alzheimer's disease symptoms following fecal microbiota transplantation: a case report. *J Int Med Res*. (2020) 48:300060520925930. doi: 10.1177/0300060520925930

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Romanenko, Kholin, Koliada and Vaiserman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.